Novel Use of Cryptotanshinone

• US 20140134138A1
• Filed: 11/06/2013
• Published: 05/15/2014
• Est. Priority Date: 10/01/2010
• Status: Active Grant

• Current Assignee: Catholic University Industry Academic Cooperation Foundation
• Original Assignee: Catholic University Industry Academic Cooperation Foundation
• Inventors: Shin, Jin Hee, Kim, Kyung Soo, Lee, Il Kyu
• Granted Patent: US 9,233,128 B2
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: C12N 2501/999 Small molecules not provided for elsewhere
• CPC Class Codes: C12N 2506/1384 from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0654 Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth

Abstract

Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. When the cryptotanshinone is treated to the MSCs, the differentiation into osteoblasts is stimulated, and thus osteogenesis of a patient may be stimulated by directly transplanting the differentiation-induced MSCs to the patient. Accordingly, the composition or osteogenesis stimulator may be used to treat patients having disability requiring stimulation of osteogenesis such as osteoporosis, bone fracture, bone grafting including alveolar bone grafting for implant placement, or other bone defects.

Claims

1. A method for stimulating differentiation of mesenchymal stem cells (MSCs) into osteoblasts, comprising administration of a composition comprising cryptotanshinone.

2. The method according to claim 1, wherein the cryptotanshinone is included at a concentration of 1 to 50 μ

M.

3. The method of claim 1, wherein the composition further comprises MSCs.

4. The method according to claim 3, wherein the composition is grafted to patients having osteoporosis, bone fracture or bone defects, or requiring bone grafting.

5. The method according to claim 3, wherein the MSCs are obtained from tissue, bone marrow, cord blood, blood, or body fluid.

6. The method according to claim 5, wherein the tissue is an adipose tissue.

7. The method according to claim 3, wherein the composition further comprises a carrier.

8. The method according to claim 3, wherein the cryptotanshinone is included at a concentration of 1 to 100 μ

M.

9. The method according to claim 3, wherein an effective amount of the MSCs is 1×

104 to 1×

106 cells/kg.